Clinical trials: Adolescents With Obesity
Pediatric Obesity, Childhood Obesity
A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents
The primary objective of this study is to describe the pharmacokinetic profiles of VI-0521 in obese adolescents.
- Trial name
- NCT02714062
- Testing
- VI-0521 Mid Dose, VI-0521 Top Dose
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- VIVUS LLC
Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
- Trial name
- NCT07836270
- Testing
- Ecnoglutide Injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity.
- Trial name
- NCT02918279
- Testing
- Liraglutide
- Where
- 33 sites in United States, Belgium and 3 more
- Volunteers
- 251 people
- Sponsor
- Novo Nordisk A/S
Adolescents With Obesity
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
The study is a first-in-pediatric assessment of the safety, tolerability, and pharmacokinetic characteristics of multiple doses of IBI362 in Chinese adolescent subjects with obesity.
- Trial name
- NCT06536023
- Testing
- IBI362
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity.
- Trial name
- NCT06075667
- Testing
- Tirzepatide
- Where
- 33 sites in United States, Canada and 4 more
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study.
- Trial name
- NCT07253285
- Testing
- Cagrilintide, Semaglutide
- Where
- 121 sites in United States, Australia and 24 more
- Volunteers
- 460 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Overweight, Obesity
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy"…
- Trial name
- NCT04102189
- Testing
- Semaglutide
- Where
- 51 sites in United States, Austria and 6 more
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with…
- Trial name
- NCT06672939
- Testing
- Orforglipron
- Where
- 34 sites in United States, Israel and 4 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Obese Adolescents, Obesity
A Study of XW003 Injection in Chinese Adolescents With Obesity
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity
- Trial name
- NCT07143227
- Testing
- XW003 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Weight Gain
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related…
- Trial name
- NCT06439277
- Testing
- Tirzepatide
- Where
- 69 sites in United States, Argentina and 10 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Obesity
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection.
- Trial name
- NCT06571383
- Testing
- Semaglutide
- Where
- 93 sites in United States, Belgium and 11 more
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy"…
- Trial name
- STEP Young (NCT05726227)
- Testing
- Semaglutide
- Where
- 56 sites in United States, Austria and 8 more
- Volunteers
- 212 people
- Sponsor
- Novo Nordisk A/S
Adolescents With Obesity or Overweight With Weight-Related Comorbidities
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight.
- Trial name
- NCT07255209
- Testing
- IBI362
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Adolescent Obesity, Obesity in Adolescence
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
This study is being conducted to assess weight loss efficacy, as determined by changes in body mass index (BMI), and safety of VI-0521 (Qsymia®) or placebo, taken for 56 weeks accompanied by a lifestyle modification program in…
- Conditions
- Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
- Trial name
- NCT03922945
- Testing
- VI-0521 oral capsule, Lifestyle Modification
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- VIVUS LLC
Overweight and Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity
The aim of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS9531 injection compared with placebo in adolescents with obesity
- Trial name
- NCT07559136
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity
Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
This study will be conducted to demonstrate weight loss efficacy by change in body mass index (BMI) and safety in adolescents age 12 to 17 years (inclusive) during 52 weeks of treatment with Belviq XR 20 milligrams (mg)…
- Trial name
- NCT03338296
- Testing
- lorcaserin hydrochloride XR
- Where
- 16 sites in United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.